SAB Biotherapeutics (SABS) Competitors

Agenus (NASDAQ:AGEN) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.

Which has better earnings & valuation, AGEN or SABS?

SAB Biotherapeutics has lower revenue, but higher earnings than Agenus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$159.63M	0.56	-$245.76M	-$12.84	-0.33
SAB Biotherapeutics	$2.24M	10.38	-$42.19M	N/A	N/A

Does the MarketBeat Community prefer AGEN or SABS?

Agenus received 441 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 81.25% of users gave SAB Biotherapeutics an outperform vote while only 69.60% of users gave Agenus an outperform vote.

Company	Underperform	Outperform
Agenus	Outperform Votes 467 69.60%	Underperform Votes 204 30.40%
SAB Biotherapeutics	Outperform Votes 26 81.25%	Underperform Votes 6 18.75%

Which has more risk and volatility, AGEN or SABS?

Agenus has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of AGEN or SABS?

61.5% of Agenus shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 4.6% of Agenus shares are held by insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media refer more to AGEN or SABS?

In the previous week, Agenus had 13 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 19 mentions for Agenus and 6 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.53 beat Agenus' score of 0.12 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer AGEN or SABS?

Agenus presently has a consensus price target of $10.50, indicating a potential upside of 147.06%. SAB Biotherapeutics has a consensus price target of $12.40, indicating a potential upside of 392.06%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
SAB Biotherapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is AGEN or SABS more profitable?

Agenus has a net margin of -144.94% compared to SAB Biotherapeutics' net margin of -1,450.14%. Agenus' return on equity of 0.00% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	-144.94%	N/A	-77.23%
SAB Biotherapeutics	-1,450.14%	-94.04%	-65.68%

Summary

SAB Biotherapeutics beats Agenus on 9 of the 16 factors compared between the two stocks.